4.7 Review

Bacterial interference for the prevention and treatment of infections

期刊

出版社

ELSEVIER
DOI: 10.1016/j.ijantimicag.2008.01.024

关键词

bacterial interference; upper respiratory tract infection; urogenital tract infection; gastrointestinal infection

向作者/读者索取更多资源

Bacterial interference refers to the antagonism between bacterial species during the process of surface colonisation and acquisition of nutrients. The clinical evidence on the potential applications of microorganisms for the prevention and/or treatment of infections in the upper respiratory, urogenital and gastrointestinal tracts was reviewed through the PubMed and Scopus databases. Data regarding factors that may affect the human microflora, thus contributing to tissue colonisation from potential pathogens, were also retrieved. The clinical evidence for application of the interfering ability of non-virulent bacteria to prevent or treat infections has been rather limited, although promising for certain purposes. A number of relevant preliminary trials suggest that in the upper respiratory tract the rate of recurrence of otitis media or streptococcal pharyngotonsillitis appears to decrease using selected bacteria with inhibitory ability against common pathogens of upper respiratory tract in combination with appropriate antibiotic treatment. Regarding the urogenital tract, specific non-pathogenic strains of Escherichia coli and probiotic organisms were successfully applied to decrease the recurrence of local infections. The interfering ability of specific probiotic organisms (strains of Lactobacilli and Bifidobacteria) within the gastrointestinal tract against common pathogens was also demonstrated. In conclusion, randomised controlled trials are warranted to investigate the effectiveness and safety of potential applications of the principle of bacterial interference in the prevention and treatment of infections of various sites. Such trials should initially employ selected strains of probiotics for which there are preliminary data regarding their effectiveness and lack of common or serious toxicity. (c) 2008 Elsevier B. V. and the International Society of Chemotherapy. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
Review Infectious Diseases

Lenacapavir: A novel injectable HIV-1 capsid inhibitor

Allison M. Hitchcock, Wesley D. Kufel, Keri A. Mastro Dwyer, Eric F. Sidman

Summary: Lenacapavir is a novel HIV-1 treatment option for patients with multidrug-resistant (MDR) HIV-1 infection. It has a favorable pharmacokinetic profile and has shown good tolerability and efficacy in clinical trials.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2024)

Article Infectious Diseases

Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort

Roberta Gagliardini, Alessandro Tavelli, Stefano Rusconi, Sergio Lo Caputo, Vincenzo Spagnuolo, Maria Mercedes Santoro, Andrea Costantini, Alessandra Vergori, Franco Maggiolo, Andrea Giacomelli, Giulia Burastero, Giordano Madeddu, Eugenia Quiros Roldan, Antonella d'Arminio Monforte, Andrea Antinori, Alessandro Cozzi-Lepri

Summary: This study evaluated multiple treatment failures to modern antiretroviral therapy in HIV-infected individuals and found that approximately 4% of them were difficult to treat. The difficult to treat group, compared to the non-difficult to treat group, was characterized by older age, higher prevalence of AIDS, lower CD4+ cell count, and higher risk of treatment failure.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2024)